Medical Device News Magazine

St. Luke’s Provides Treatment for COVID ‘Long Haulers’

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

April 16, 2021

St. Luke’s has introduced its new COVID Recovery Clinic, a program dedicated to the treatment of post-COVID-19 patients with lingering symptoms.

St. Luke’s recognizes the prevalence of “long COVID” symptoms and the need to care for patients afflicted by these symptoms appropriately.  Incorporating the expertise of a half dozen different kinds of medical specialists, the program promises a coordinated, multidisciplinary approach to Post-Acute Sequelae of COVID, known as PASC.  Participants will benefit from specialized evaluation and a personalized treatment plan.

“Many people recovering from COVID continue to have long-lasting symptoms that impact their day-to-day lives. St. Luke’s is committed to helping these patients get access to the most appropriate care so they can find relief,” said St. Luke’s Senior Regional Medical Director Dennis McGorry, MD, who is spearheading the program.

Nationally, PASC of varying severity is being reported in up to 30% of adults and children following COVID infection.

Most typical COVID cases resolve in four weeks, explained Jeffrey Jahre, MD, St. Luke’s Vice President of Medical & Academic Affairs and Section Chief Emeritus of Infectious Diseases.  But for some, the symptoms aren’t going away. “Patients are going to their doctor, asking, ‘What’s wrong with me?’ In many cases, people are not getting the appropriate care.”

The most common after-effects these patients, or “long haulers,” experience include extreme fatigue, memory impairment, known as “brain fog,” anxiety and depression, breathing difficulty and heart muscle irregularities or irregular heartbeats.

Patients with persistent symptoms beyond four weeks are advised to go to their St. Luke’s primary care physician, who will be able to evaluate them and may refer them to the COVID Recovery Clinic for further treatment by appropriate medical specialists.

Depending on a patient’s specific symptoms and their severity, treatment can include cognitive and memory retraining, physical and occupational therapy, medication and group therapy for behavioral health issues as well as other interventions to address neurologic, pulmonary and cardiac problems.

St. Luke’s has taken steps to help providers manage PASC, such as building a “smart set” algorithm into the electronic medical record system. The smart set guides physicians on ordering tests and imaging scans based on patients’ symptoms.

While some COVID after-effects may be mild, McGorry said, “The key is not missing something serious like a pulmonary embolism or cardiomyopathy (heart muscle issue) in these patients.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”